RaySearch Laboratories

RaySearch Laboratories (AB publ) is a <a href="/facts/Sweden/u3qC7lyj">Swedish</a> <a href="/facts/Medical_technology/8kAt4ub0">medical technology</a> company that develops software used in <a href="/facts/Radiation_therapy/j60q5EC6">radiation therapy</a> of <a href="/facts/Cancer/PVW6n1D0">cancer</a>. The company markets its products worldwide and has <a href="/facts/Subsidiary/l25YN38x">subsidiaries</a> in the <a href="/facts/United_States/P0sCdLe5">United States</a>, <a href="/facts/Singapore/CQDkhUvD">Singapore</a>, <a href="/facts/Belgium/YKuMXP5j">Belgium</a>, <a href="/facts/France/CxIeIKM3">France</a>, <a href="/facts/Germany/paluuWBX">Germany</a>, and the <a href="/facts/United_Kingdom/kuPAILt2">United Kingdom</a>.
RaySearch markets the RayStation treatment planning system. Its products are also distributed through licensing agreements with medical technology companies including <a href="/facts/Accuray/3jqslKW1">Accuray</a>, Mevion, <a href="/facts/Philips/Xp4uczGg">Philips</a>, Nucletron, <a href="/facts/Ion_Beam_Applications/GMmQEHwE">IBA</a>, Varian, and <a href="/facts/Brainlab/MmjP1wg6">Brainlab</a>.
RaySearch is a <a href="/facts/Public_company/tnJQvSdR">public company</a> listed on the <a href="/facts/Nasdaq_Stockholm/wAVPR550">Nasdaq Stockholm</a> stock exchange. Effective on 4 January 2016, RaySearch series B share (RAY B) was moved from the Small Cap to the Mid Cap segment of Nasdaq Stockholm, which is the segment for companies with a market value of at least 150 million euros and up to one billion.

RaySearch Laboratories open-in-new

RaySearch Laboratories